Key Investor Metrics
Market Cap
65.92B
PKRForward P/E Ratio
17.01
vs 21.7 (Peers)EPS (FY 2025)
0.85
PKRDebt/Equity Ratio
0.24
Low LeverageFinancial Health & Performance
Searle's financial performance shows resilience. After a significant loss in 2024, the company returned to profitability in 2025. Revenue has seen a slight dip in 2025 after consistent growth, reflecting a challenging economic environment.
Shareholder Value & Dividends
Historically, Searle has rewarded shareholders with both cash dividends and bonus shares. The chart below shows the cash dividend percentage declared. In recent years (2022-2025), the focus has shifted towards bonus shares and reinvestment for growth.
PESTLE Analysis: Pharma Sector
The company operates within the complex Pakistani pharmaceutical landscape, influenced by several macro-environmental factors.
Political
- Government drug pricing policies (DRAP).
- Deregulation of non-essential drugs.
- General political & economic stability.
Economic
- PKR devaluation impacting import costs.
- High inflation rates.
- Reliance on imported raw materials (APIs).
- Rising healthcare spending.
Social
- Large and growing population.
- Increasing health awareness & demand.
- Preference for generic drugs.
Technological
- Investment in R&D and biotech.
- Adoption of modern manufacturing processes.
- Need for technology transfer.
Legal
- Strict regulatory framework (DRAP).
- Patent laws and intellectual property rights.
- Anti-corruption and transparency measures.
Environmental
- Pharmaceutical waste disposal regulations.
- Environmental manufacturing standards.
- Focus on sustainable practices.
Future Outlook & Valuation
Analysts project strong future earnings growth. Based on forward P/E, the stock appears undervalued compared to its peers. However, the average analyst price target suggests a potential downside from its current price.
Forecast Revenue Growth
15.6% / annum
Forecast Earnings Growth
34.4% / annum
Analyst 12-Month Target
PKR 104.35